CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug

investors.com/news/technology/cormedix-stock-defencath-large-dialysis-organization

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath.
The post CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-06-23 18:51:07.
The Entire Business World on a Single Page. Free to Use →